172 related articles for article (PubMed ID: 10379532)
1. [Molecular alterations in Barrett's esophagus and adenocarcinoma].
Ozawa S; Ando N; Kitagawa Y; Ueda M; Kitajima M
Nihon Geka Gakkai Zasshi; 1999 Mar; 100(3):235-9. PubMed ID: 10379532
[TBL] [Abstract][Full Text] [Related]
2. [Carcinogenesis of Barrett's esophagus].
Endo T; Sugawara N; Shinomura Y
Nihon Rinsho; 2005 Aug; 63(8):1357-61. PubMed ID: 16101221
[TBL] [Abstract][Full Text] [Related]
3. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
[TBL] [Abstract][Full Text] [Related]
4. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.
Cameron AJ; Ott BJ; Payne WS
N Engl J Med; 1985 Oct; 313(14):857-9. PubMed ID: 4033716
[TBL] [Abstract][Full Text] [Related]
5. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of p53 in Barrett's oesophagus.
Krishnadath KK; van Blankenstein M; Tilanus HW
Eur J Gastroenterol Hepatol; 1995 Jan; 7(1):81-4. PubMed ID: 7866817
[TBL] [Abstract][Full Text] [Related]
7. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
8. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
9. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
10. [Clinical outline of Barrett's esophagus].
Kuwano H; Sohda M; Kato H; Miyazaki T; Kimura H
Nihon Rinsho; 2005 Aug; 63(8):1372-8. PubMed ID: 16101224
[TBL] [Abstract][Full Text] [Related]
11. Progression to cancer in Barrett's esophagus is associated with genomic instability.
Rabinovitch PS; Reid BJ; Haggitt RC; Norwood TH; Rubin CE
Lab Invest; 1989 Jan; 60(1):65-71. PubMed ID: 2911184
[TBL] [Abstract][Full Text] [Related]
12. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
13. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
[TBL] [Abstract][Full Text] [Related]
15. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
16. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
[TBL] [Abstract][Full Text] [Related]
17. APC gene alterations in Barrett's metaplasia are implicated at an early stage in the carcinogenesis of esophageal adenocarcinoma.
Fein M
Am J Gastroenterol; 1997 Feb; 92(2):359-60. PubMed ID: 9040229
[No Abstract] [Full Text] [Related]
18. Barrett's esophagus: the biology of neoplastic progression.
Neshat K; Sanchez CA; Galipeau PC; Levine DS; Reid BJ
Gastroenterol Clin Biol; 1994; 18(1 Pt 2):D71-6. PubMed ID: 8013790
[No Abstract] [Full Text] [Related]
19. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
20. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
